Trials / Active Not Recruiting
Active Not RecruitingNCT03930498
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-1 blocking antibody | Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd. |
| DRUG | Chemotherapy | Cisplatin and Gemcitabine |
| RADIATION | IMRT | IMRT 60-66Gy, 1.8-2.0Gy/f/day |
Timeline
- Start date
- 2020-03-12
- Primary completion
- 2023-11-22
- Completion
- 2025-12-01
- First posted
- 2019-04-29
- Last updated
- 2025-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03930498. Inclusion in this directory is not an endorsement.